Want to see GB:PRM full AI Analyst Report?
PRM Stock Chart & Stats
2.85 p
-0.10 p(-2.84%)
At close: 4:00 PM EST
2.85 p
-0.10 p(-2.84%)
Day’s Range― - ―
52-Week Range1.20 p - 4.40 p
Previous CloseN/A
Volume41.42K
Average Volume (3M)476.64K
Market Cap
£6.38M
Enterprise Value22.37 p
Total Cash (Recent Filing)£781.00K
Total Debt (Recent Filing)£15.77M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding350,724,900
10 Day Avg. Volume209,671
30 Day Avg. Volume476,642
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-0.77
Price to Sales (P/S)1.96
P/FCF Ratio-51.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Proteomics ServicesThe company’s core fee-for-service proteomics business is a durable, project-based model serving pharma, biotech and academic research. Specialized mass‑spectrometry capabilities create repeatable project revenue streams tied to drug discovery and biomarker workflows, supporting stable demand over 2–6 months.
Proprietary Reagents And Software/IP PotentialOwning proprietary reagents, software and IP provides optional long‑term upside beyond services. Successful licensing or product commercialization can create higher‑margin, recurring royalty or product revenues and diversify income, providing a structural path to improve margins and reduce service concentration risk.
Near-term Cash Flow ImprovementImproved operating and free cash flow in 2025 signals better cost control and working capital management versus prior years. While still negative, the smaller cash shortfall reduces immediate refinancing pressure and gives management more runway to stabilize operations and pursue targeted commercialization or partnership steps.
Bears Say
Declining Revenue And Negative Gross ProfitA multi-year swing from earlier profitability to persistent revenue decline and negative gross profit indicates weak demand coverage and poor fixed cost absorption. Continued operating losses erode reserves and limit ability to reinvest in sales, R&D or scale proprietary products without external funding.
High Leverage And Negative EquityDebt materially exceeding assets and negative shareholders’ equity create elevated refinancing and covenant risk. This constrained capital structure limits strategic flexibility, increases financing costs or dilution risk, and makes sustaining operations or expanding commercial activities more difficult without external capital or restructuring.
Volatile Cash Generation And Limited Self-fundingHistoric cash‑flow volatility and persistent negative free cash flow reduce resilience to revenue shocks and limit internal funding for product development or capacity. Reliance on external financing increases execution risk and could force dilutive equity raises or cutbacks to R&D and commercial initiatives.
Proteome Sciences News
PRM FAQ
What was Proteome Sciences PLC’s price range in the past 12 months?
Proteome Sciences PLC lowest share price was 1.20 p and its highest was 4.40 p in the past 12 months.
What is Proteome Sciences PLC’s market cap?
Proteome Sciences PLC’s market cap is £6.38M.
When is Proteome Sciences PLC’s upcoming earnings report date?
Proteome Sciences PLC’s upcoming earnings report date is Apr 01, 2027 which is in 250 days.
How were Proteome Sciences PLC’s earnings last quarter?
Currently, no data Available
Is Proteome Sciences PLC overvalued?
According to Wall Street analysts Proteome Sciences PLC’s price is currently Overvalued.
Does Proteome Sciences PLC pay dividends?
Proteome Sciences PLC does not currently pay dividends.
What is Proteome Sciences PLC’s EPS estimate?
Proteome Sciences PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteome Sciences PLC have?
Proteome Sciences PLC has 350,724,900 shares outstanding.
What happened to Proteome Sciences PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Proteome Sciences PLC?
Currently, no hedge funds are holding shares in GB:PRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also offers top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, as well as to academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.